GlaxoSmithKline announces USD 1.65 billion of acquisition Reliant Pharmaceutical
Pronova BioPharma ASA notes the announcement of a proposed USD 1.65 billion acquisition between GlaxoSmithKline PLC and Reliant Pharmaceuticals, Inc. GlaxoSmithKline is one of the world`s leading research-based pharmaceutical and healthcare companies and its proposed acquisition of Reliant, whose lead product is based on Pronova BioPharma`s API and branded as Lovaza in the US, is a significant endorsement of the product`s current success and future opportunity within the US market, according to the company. Lovaza is the only omega-3 derived pharmaceutical approved by the United States food and Drug Administration (FDA) for the treatment of very high triglycerides.
The acquisition is subject to approval by the US Federal Trade Commission and is expected to conclude before year-end.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.